ESR1 and breast cancer: The authors characterized the cellular composition of the bone niche in the presence of triple negative (Estrogen receptor (ER-), progesterone receptor (PR-) and HER/Neu -negative, MDA-MB-231) or estrogen-receptor positive (ER+, MCF-7) breast cancer metastases in vivo.